122455-85-0

Basic information

• Product Name: 5-AMINO-4-FLUORO-2-METHYLPHENOL
• Synonyms: 5-AMINO-4-FLUORO-2-METHYLPHENOL;4-Amino-5-fluoro-o-cresol;4-Amino-5-fluoro-o-methylphenol;5-Amino-4-fluoro-2-methylphenol 98%;5-Amino-4-fluoro-2-methylphenol98%;5-Amino-4-fluoro-o-cresol (OH=1);2-Fluoro-5-hydroxy-4-methylaniline, 4-Amino-5-fluoro-2-hydroxytoluene;2-Methyl-4-fluoro-5-aminophenol
• CAS NO: 122455-85-0
• Molecular Formula: C₇H₈FNO
• Molecular Weight: 141.14
• Product Categories: pharmacetical;Phenol&Thiophenol&Mercaptan
• Mol File: 122455-85-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 147 °C
• Boiling Point: 270.958 °C at 760 mmHg
• Flash Point: 117.672 °C
• Appearance: /
• Density: 1.276 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.39±0.23(Predicted)
• CAS DataBase Reference: 5-AMINO-4-FLUORO-2-METHYLPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-4-FLUORO-2-METHYLPHENOL(122455-85-0)
• EPA Substance Registry System: 5-AMINO-4-FLUORO-2-METHYLPHENOL(122455-85-0)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 122455-85-0(Hazardous Substances Data)

Usage

General Description

5-AMINO-4-FLUORO-2-METHYLPHENOL is a chemical compound with the molecular formula C7H8FNO. It is an aromatic compound containing an amine and a phenol group, as well as a fluorine and a methyl substituent. 5-AMINO-4-FLUORO-2-METHYLPHENOL is used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has also been studied for its potential antioxidant and antimicrobial properties. Additionally, 5-AMINO-4-FLUORO-2-METHYLPHENOL is known for its ability to inhibit the production of melanin, making it a potential ingredient in skincare and cosmetic products aimed at lightening skin tone and reducing hyperpigmentation.

InChI:InChI=1/C7H8FNO/c1-4-2-5(8)6(9)3-7(4)10/h2-3,10H,9H2,1H3

Upstream product

• 452-72-2 4-fluoro-2-methylphenol 
• 7439-89-6 iron 
• 122455-84-9 2-methyl-4-fluoro-5-nitrophenol 
• 122455-86-1 (4-fluoro-2-methylphenyl)methylcarbonate 

Downstream Products

• 1225278-75-0 5-(4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)pyrimidin-2-yloxy)-2-fluoro-4-methylbenzenamine 
• 197359-30-1 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethoxy)cinnoline hydrochloride 
• 197359-27-6 6-chloro-4-(2-fluoro-5-hydroxy-4-methylanilino)cinnoline hydrochloride 
• 791763-86-5 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]cinnoline 
• 197359-33-4 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)cinnoline 
• 205447-79-6 2-acetamido-5-(2-fluoro-5-hydroxy-4-methylanilino)-1,8-naphthyridine hydrochloride 
• 205447-75-2 6-cyano-4-(2-fluoro-5-hydroxy-4-methylanilino)-7-methoxyquinoline hydrochloride 
• 205448-09-5 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinoline 

Relevant articles and documents

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

Chemical compounds

The invention relates to quinazoline derivatives of the formula: [wherein: Y1represents —O—, —S—, —CH2—, —SO—, —SO2—, —NR5CO—, —CONR6—, —SO2NR7—, —NR8SO2— or —NR9— (wherein R5, R6, R8and R9each independently represents hydrogen, alkyl or alkoxyalkyl); R1represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino. R2represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro; m is an integer from 1 to 5; R3represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

SUBSTITUTED QUINAZOLINES

-